U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06858878) titled 'Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight' on Feb. 28.
Brief Summary: The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Study Start Date: March 17
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Intervention:
DRUG: Maridebart cafraglutide
Maridebart cafraglutide will be adminstered SC.
DRUG: Placebo
Placebo will be adminstered SC.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Amgen
Published by HT...